Barclays Flips From Bear to Bull on Alvotech — But Can a Factory Fix Unlock a U.S. Biosimilar Empire?

Shares of Alvotech surged 5.25% to ISK 642.00 on September 16 after Barclays analyst Glen Santangelo reversed course on the biosimilar maker, upgrading it from Underweight (a sell recommendation) to Overweight (a buy) and doubling his price target from $4.00 to $8.00. The swing amounts to a stunning about-face for the same analyst who, just six months ago, cut the target to $4 and flagged concerns about the company's financial flexibility and high debt levels. The catalyst: a cleared factory inspection and a wave of pending U.S. drug approvals.

• A Clean Factory Report Changes Everything. The FDA closed its May 2026 inspection of Alvotech's Reykjavik, Iceland manufacturing facility and classified it as "Voluntary Action Indicated," or VAI — meaning regulators found minor issues but no serious violations. Regulatory clearance at the manufacturing level is often a prerequisite for commercial approvals , so the VAI stamp removes the single biggest obstacle that had frozen investor confidence.

• Three U.S. Drug Decisions Loom by Year-End. Alvotech resubmitted applications for lower-cost versions of the arthritis drug Simponi and the eye-disease treatment Eylea, with decisions anticipated in Q4 2026.

The FDA also accepted a submission for a proposed copycat of the gut-disease drug Entyvio, with a decision expected in early 2027. Approval of even one product would mark Alvotech's first major U.S. commercial launch.

• Revenue Fell, but the Full-Year Bet Remains Intact. First-half adjusted revenue came in at $211.9 million, down sharply from $306.1 million a year earlier , largely because a manufacturing improvement program disrupted output and product availability. Management nonetheless maintained full-year guidance of $650–$700 million in revenue and $180–$220 million in adjusted EBITDA. Hitting the high end requires a massive second-half ramp — a bet on new product launches that haven't happened yet.

• Cash Is Tight While the Pipeline Burns Money. Alvotech raised roughly $165 million in a public offering and secured a $75 million term loan to bridge the gap, but its cash balance stood at just $142.8 million at mid-year.

The stock has swung between $2.94 and $9.25 over the past 52 weeks , underscoring that investors view this as a high-stakes binary outcome: either FDA approvals arrive on time and unlock U.S. revenue, or the cash runway tightens uncomfortably.